Valeant Pharma (VRX) EBITDA Was North of $1B, Which Was Better than Feared - Evecore ISI Raffat
Evecore ISI analyst Umer Raffat weighed in on Valeant Pharma (NYSE: VRX) quarter. He notes that based on his investor conversations, buyside sentiment had MASSIVELY shifted when the stock moved from ~$30 to <$20.
He said there was fears that Q3 EBITDA may be <$1B and that didn't happen - Valeant tracked at $1.16B.
He said the new 2016 EBITDA guidance ($4.25-$4.35B) appears a touch below consensus, "but even if you straight-line Q3 EBITDA into Q4, you get to consensus-like $4.4-4.5B (and recall there are price increases + more SG&A cuts in Q4)."
Elsewhere, he notes cash flow conversion better in Q3 vs Q2.
On products: Xifaxan tracked at $273M this quarter (vs $200-208M range for last quarters). In addition, new Xifaxan formulation entering Ph 3 in 2H17 as per slides (v impt from lifecycle mgmt/patent perspective). Also, Raffat notes they may be seeing early signs of improvement in derm: Jublia came out at $44M in Q3 (Vs $31M in Q2). On neuro/other, they saw sequential drops in Isuprel, Wellbutrin, Xenazine etc.
Shares of VRX are down 7.5% to $17.69 in pre-open trade.